Resistance to dual nucleoside reverse-transcriptase inhibitors in children infected with HIV clade A/E

被引：11

作者：

Lolekha, R

Sirivichayakul, S

Siangphoe, U

Pancharoen, C

Kaewchana, S

Apateerapong, W

Mahanontharit, A

Chotpitayasunondh, T

Ruxrungtham, K

Phanuphak, P

Ananworanich, J

机构：

[1] Thai Red Cross AIDS Res Ctr, Thailand Res Collaborat, Queen Sikrit Natl Inst Child Hlth, HIV NAT, Bangkok 10330, Thailand

[2] Chulalongkorn Univ, Bangkok 10330, Thailand

来源：

CLINICAL INFECTIOUS DISEASES | 2005年 / 40卷 / 02期

关键词：

D O I：

10.1086/427026

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The prevalence of nucleoside reverse-transcriptase inhibitor (NRTI) mutations was determined among 95 human immunodeficiency virus-infected Thai children who were treated with dual nucleoside reverse-transcriptase inhibitors. Almost all children had resistance to at least 1 NRTI, and approximately half of the children had resistance to multiple NRTIs. Cross-resistance to stavudine and azidothymidine was universal.

引用

页码：309 / 312

页数：4

共 16 条

[1]

Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195

[2]

D'Aquila Richard T., 2002, Top HIV Med, V10, P21

[3]

de Mendoza Carmen, 2002, HIV Clin Trials, V3, P9

[4] Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy [J].

Descamps, D ;

Flandre, P ;

Calvez, V ;

Peytavin, G ;

Meiffredy, V ;

Collin, G ;

Delaugerre, C ;

Robert-Delmas, S ;

Bazin, B ;

Aboulker, JP ;

Pialoux, G ;

Raffi, F ;

Brun-Vézinet, F .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (02) :205-211

[5] Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity [J].

Diallo, K ;

Marchand, B ;

Wei, X ;

Cellai, L ;

Götte, M ;

Wainberg, MA .

JOURNAL OF VIROLOGY, 2003, 77 (16) :8621-8632

[6] Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (Novavir trial) [J].

Joly, V ;

Flandre, P ;

Meiffredy, V ;

Brun-Vezinet, F ;

Gastaut, JA ;

Goujard, C ;

Remy, G ;

Descamps, D ;

Ruffault, A ;

Certain, A ;

Aboulker, JP ;

Yeni, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1906-1913

[7]

Masquelier B, 1999, ANTIVIR THER, V4, P69

[8] Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients [J].

Maxeiner, HG ;

Keulen, W ;

Schuurman, R ;

Bijen, M ;

de Graaf, L ;

van Wijk, A ;

Back, N ;

Kline, MW ;

Boucher, CAB ;

Nijhuis, M .

JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (08) :1070-1076

[9] Antiretroviral drug resistance among HIV-1 infected children failing treatment [J].

Mullen, J ;

Leech, S ;

O'Shea, S ;

Chrystie, IL ;

du Mont, G ;

Ball, C ;

Sharland, M ;

Cottam, F ;

Zuckerman, M ;

Rice, P ;

Easterbrook, P .

JOURNAL OF MEDICAL VIROLOGY, 2002, 68 (03) :299-304

[10] T69D/N pol mutation, human immunodeficiency virus type 1 RNA levels, and syncytium-inducing phenotype are associated with CD4 cell depletion during didanosine therapy [J].

Naugler, WE ;

Yong, FH ;

Carey, VJ ;

Dragavon, JA ;

Coombs, RW ;

Frenkel, LM .

JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (04) :448-455

← 1 2 →